LG Chem

Sinovac announced last week that China’s National Medical Products Administration has approved its Sabin-based inactivated polio vaccine (sIPV).

In its press release, the Chinese biotech said that WHO accepted its prequalification materials in early 2020 and completed site inspections this February. If prequalified, Sinovac’s sIPV would become the second Sabin-based product to gain the status after LG Chem’s in January 2021.

The Beijing Institute of Biological Products and…

Seven leading pharma companies released first-quarter 2021 financial results in May, while one Japanese firm reported full-year 2020 results for the fiscal year ending in March. (Figures exclude exchange rate and portfolio changes where applicable.)
Leading the pack, first-quarter sales for South Korea’s newly public SK Bioscience soared 397% year-over-year to $101.1 million, as its Covid-19 vaccine CMO business started “making numbers in earnest” in supplying the AstraZeneca/…

Seoul’s International Vaccine Institute (IVI) announced last week that South Korea-based Sumagen will pursue recombinant vesicular stomatitis virus (rVSV)-based vaccines against MERS and Crimean-Congo hemorrhagic fever with $1.2 million in funding, to include work on wider pandemic response platforms. The project is part of a collaboration between IVI and the government-sponsored Vaccine Innovative Technology Alliance Korea (VITAL-Korea) initiative.

Sumagen’s rVSV-based Covid-19…

The state of the hunt:

Serum Institute of India will export Covishield doses to the United Kingdom.
  COVAX unveiled initial vaccine allocations, and numerous COVAX participants received their first shipments and began administering jabs.
  Bharat Biotech’s Covaxin demonstrated 81% efficacy against symptomatic disease in an interim Phase 3 analysis.



Approved or authorized vaccines
U.S. regulators completed their signoff…

An update last week to UNICEF Supply Division’s price list for inactivated polio vaccine (IPV) shows that South Korea-based LG Chem’s recently prequalified Sabin-based shot is now the lowest-cost five-dose IPV available.

LG Chem’s price is $1.75 per dose in 2021 and falls to $1.50 in 2022. Denmark’s AJ Vaccines has the next cheapest five-dose IPV at $2.45 per dose in 2021 and as low as $1.90 in 2022. Serum Institute of India’s Bilthoven-manufactured shot is 80% more costly than its…

WHO added LG Chem’s Sabin-based inactivated polio vaccine (sIPV) to its list of prequalified products last month, making the shot the first PQ’d IPV to use the safer attenuated Sabin poliovirus.

In 2014, GSK accidentally spilled 45 liters of liquid contaminated by the wild-type Salk poliovirus into a Belgian river.

The third edition of WHO’s Global Action Plan to minimize poliovirus facility-associated risk (GAP III, published in 2015) opposed new Salk IPV facilities because of…


The state of the hunt:

With their mRNA vaccine showing an interim efficacy rate above 90%, Pfizer and BioNTech may have the necessary data to apply for U.S. FDA Emergency Use Authorization this month.
  Eli Lilly snagged the first FDA EUA for an anti-SARS-CoV-2 monoclonal antibody.
  Indonesia and Morocco laid out plans for Covid-19 mass immunization campaigns before year-end.



Phase 3 candidates:

Pfizer/BioNTech’s shot more…

Thirteen leading pharma companies released third-quarter 2020 financial results in October, and Japan’s Takeda (whose fiscal year ends in March) reported first-half numbers.

Leading the pack, bioMérieux’s quarterly sales soared 26.5% to $924 million, surpassing consensus estimates by 7%. The French diagnostics firm attributed the “exceptional momentum” to strong demand for its BioFire FilmArray testing solutions line and compatible Covid-19 tests. The company expects full-year sales…

Seven leading pharma companies released second-quarter financial results in August. (Figures exclude exchange rate and portfolio changes where applicable.)

Leading the round, South Korea’s LG Chem posted 2.3% growth year-over-year, reaching $6 billion in quarterly sales. LG Life Sciences—which houses vaccines and drugs—saw quarterly sales up 4% from last year to $138 million. Life Sciences signed multiple deals in August, including an agreement worth up to $98.5 million with Britain’s…

Thirteen leading pharma companies released first-quarter 2020 financial results in April. Covid-19 dominated the reports, spurring short-term sales gains for many companies while generating longer-term uncertainty about the duration and impact of the pandemic. Ahead of the reports, some analysts had drastically lowered estimates in anticipation of a slowdown in routine medical procedures.

(Figures exclude exchange rate and portfolio changes where applicable.)

Leading the…